CN112426462B - Hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy and preparation method thereof - Google Patents
Hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy and preparation method thereof Download PDFInfo
- Publication number
- CN112426462B CN112426462B CN202110008288.7A CN202110008288A CN112426462B CN 112426462 B CN112426462 B CN 112426462B CN 202110008288 A CN202110008288 A CN 202110008288A CN 112426462 B CN112426462 B CN 112426462B
- Authority
- CN
- China
- Prior art keywords
- extract
- tea
- essential oil
- eye patch
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 41
- 208000003569 Central serous chorioretinopathy Diseases 0.000 title claims abstract description 26
- 238000009098 adjuvant therapy Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 26
- 244000269722 Thea sinensis Species 0.000 claims abstract description 118
- 239000000284 extract Substances 0.000 claims abstract description 107
- 235000013616 tea Nutrition 0.000 claims abstract description 101
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 75
- 239000000341 volatile oil Substances 0.000 claims abstract description 53
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000000049 pigment Substances 0.000 claims abstract description 26
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 26
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 26
- 229940026510 theanine Drugs 0.000 claims abstract description 26
- 235000010254 Jasminum officinale Nutrition 0.000 claims abstract description 24
- 240000005385 Jasminum sambac Species 0.000 claims abstract description 24
- 235000009569 green tea Nutrition 0.000 claims abstract description 18
- 240000008365 Celosia argentea Species 0.000 claims abstract description 17
- 235000000722 Celosia argentea Nutrition 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 17
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 17
- 240000003065 Malva verticillata Species 0.000 claims abstract description 16
- 235000002384 Malva verticillata Nutrition 0.000 claims abstract description 16
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 16
- 235000011477 liquorice Nutrition 0.000 claims abstract description 16
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 15
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000002861 polymer material Substances 0.000 claims abstract description 14
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 12
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract description 12
- 229940067866 dandelion extract Drugs 0.000 claims abstract description 12
- 235000020691 dandelion extract Nutrition 0.000 claims abstract description 12
- 239000008213 purified water Substances 0.000 claims abstract description 12
- 229940119485 safflower extract Drugs 0.000 claims abstract description 12
- 239000000600 sorbitol Substances 0.000 claims abstract description 12
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims abstract description 12
- 230000002829 reductive effect Effects 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 24
- 239000003480 eluent Substances 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 238000005406 washing Methods 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 239000013078 crystal Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 241000628997 Flos Species 0.000 claims description 10
- 238000001694 spray drying Methods 0.000 claims description 10
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 10
- 239000004745 nonwoven fabric Substances 0.000 claims description 8
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 8
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 8
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003729 cation exchange resin Substances 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000009724 Salvia extract Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 5
- 238000011278 co-treatment Methods 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 241000132012 Atractylodes Species 0.000 claims description 4
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 238000010030 laminating Methods 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000003463 adsorbent Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 27
- 201000010099 disease Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 230000004438 eyesight Effects 0.000 abstract description 16
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract description 11
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract description 11
- 230000037303 wrinkles Effects 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 239000003205 fragrance Substances 0.000 abstract description 2
- 230000002936 tranquilizing effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 9
- 244000020518 Carthamus tinctorius Species 0.000 description 8
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 241000245665 Taraxacum Species 0.000 description 6
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 201000010183 Papilledema Diseases 0.000 description 4
- 206010038886 Retinal oedema Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000012156 elution solvent Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 201000011195 retinal edema Diseases 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000219780 Pueraria Species 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- BWWAFUZQSLIIIH-UHFFFAOYSA-N 2-phenyl-3H-chromen-3-id-4-one Chemical compound O1C(=[C-]C(=O)C2=CC=CC=C12)C1=CC=CC=C1 BWWAFUZQSLIIIH-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000002189 macula lutea Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- BDBMLMBYCXNVMC-UHFFFAOYSA-O 4-[(2e)-2-[(2e,4e,6z)-7-[1,1-dimethyl-3-(4-sulfobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS(O)(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C BDBMLMBYCXNVMC-UHFFFAOYSA-O 0.000 description 1
- 241001075517 Abelmoschus Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241001522633 Betula utilis subsp. albosinensis Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 239000008830 Carthamus tinctorius Honghua extract Substances 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- 235000013939 Malva Nutrition 0.000 description 1
- 241000382417 Malva Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 241000123069 Ocyurus chrysurus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000009277 Panax notoginseng extract Substances 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 238000000658 coextraction Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000873 fovea centralis Anatomy 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy, which mainly comprises the following raw materials in percentage by weight: 0.01-0.04% of tea essential oil, 0.2-0.8% of tea polyphenol, 0.1-0.6% of theanine, 0.1-0.6% of tea pigment, 0.01-0.04% of jasmine essential oil, 0.2-1.0% of safflower extract, 0.2-1.0% of salvia miltiorrhiza extract, 0.2-1.5% of kudzu root extract, 0.2-1.5% of dandelion extract, 0.2-1.5% of feather cockscomb seed extract, 0.2-1.5% of rhizoma atractylodis extract, 0.2-1.0% of cluster mallow seed extract, 0.2-1.0% of liquorice extract, 10-25% of high polymer material, 20-30% of glycerol, 0.1-0.5% of citric acid, 1-3% of sorbitol, 0.1-0.3% of aluminum hydroxide and the balance of purified water. The hydrogel eye patch is an external patch, has the fragrance of jasmine green tea, can promote absorption of subretinal effusion, shorten course of disease, improve vision, and has effects of tranquilizing mind, removing wrinkle, etc.
Description
Technical Field
The invention belongs to the technical field of eye patches, and particularly relates to a hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy and a preparation method thereof.
Background
Central Serous Chorioretinopathy (CSC), known as "intermediate serous fluid", is a common lesion of macular portion of the fundus oculi, which is characterized by macular region, mainly macular region, and localized serous superficial detachment of retinal neuroepithelium of the retina nearby, caused by retinal pigment epithelium damage. The disease is mostly seen in men of 20-45 years old, and is a self-limiting disease with the onset of monocular disease. The patient shows sudden monocular vision loss, blurred vision, poor color, diminished vision, distortion of straight lines, etc. Although most patients can recover themselves within 3-6 months, the patients who recover themselves are easy to relapse, and after the patients relapse for many times, irreversible damages such as visual function reduction and vision deterioration can be caused, which has great influence on the work and life of the patients.
The disease is induced by factors such as mental stress, poor sleep, emotional disorder, fatigue, irritation of smoking and wine, pathogen and systemic infection, allergic diseases, external cold influence, etc. Therefore, prevention and early treatment should be premised.
Belongs to the categories of symptoms such as Chinese traditional medicine vision awn-manow, vision blackness, vision positive and negative inclination, vision confusion and the like. It is mainly related to the dysfunction of liver, spleen and kidney. Spleen failing to transport and transform, damp turbidity rising, emotional damage to liver, liver depression, qi stagnation, qi, blood and body fluids abnormal transportation, blood stasis and damp stagnation, which are prone to cause this disease.
At present, the methods for treating CSC mainly comprise laser photocoagulation, photodynamic therapy (PDT), micro-pulse laser, transpupillary thermotherapy (TTT), indocyanine green mediated light embolism therapy and other treatment methods; however, the above treatment methods have certain limitations and adverse reactions, such as laser photocoagulation, which can accelerate the absorption of retinal edema, shorten the course of disease and reduce the incidence of diseases; but not for the cause, and cannot prevent recurrence. In the aspect of traditional Chinese medicine treatment, the treatment methods such as a traditional Chinese medicine extraction preparation, a compound preparation, an empirical formula and the like are adopted, so that the effect is better, but the traditional Chinese medicine treatment has the problems of long treatment course, inconvenience in use and the like.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a hydrogel eye patch for assisting in treating central serous chorioretinopathy, which is an external patch, has the faint scent of jasmine green tea, can promote absorption of subretinal effusion, shortens the course of disease, improves the vision, and has the effects of soothing the nerves, resisting wrinkles and the like.
The invention also provides a preparation method of the hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy.
In order to achieve the purpose, the invention adopts the following technical scheme:
a hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy is mainly composed of the following raw materials in percentage by weight: 0.01-0.04% of tea essential oil, 0.2-0.8% of tea polyphenol, 0.1-0.6% of theanine, 0.1-0.6% of tea pigment, 0.01-0.04% of jasmine essential oil, 0.2-1.0% of safflower extract, 0.2-1.0% of salvia miltiorrhiza extract, 0.2-1.5% of kudzu root extract, 0.2-1.5% of dandelion extract, 0.2-1.5% of feather cockscomb seed extract, 0.2-1.5% of atractylodes rhizome extract, 0.2-1.0% of cluster mallow seed extract, 0.2-1.0% of liquorice extract, 10-25% of high polymer material, 20-30% of glycerol, 0.1-0.5% of citric acid, 1-3% of sorbitol, 0.1-0.3% of aluminum hydroxide and the balance of purified water (preferably 40-60% of purified water).
Specifically, the polymer material is used as a hydrogel matrix, and can be one or a mixture of more than two of sodium polyacrylate, polyacrylic acid, polymethacrylic acid, polyvinyl alcohol, polyacrylamide, sodium carboxymethylcellulose and the like.
Specifically, the tea essential oil, the tea polyphenol and the theanine can be directly purchased from common commercial products, and can also be prepared by adopting the following steps:
pulverizing green tea (40 mesh), and performing CO treatment 2 Performing supercritical extraction to obtain tea essential oil, wherein the extraction temperature is 20-60 ℃, the pressure is 10-20MPa, and the extraction time is 1-6 h;
CO is introduced into 2 Adding water 10-30 times the weight of folium Camelliae sinensis residue into the folium Camelliae sinensis residue after supercritical extraction, extracting at 40-90 deg.C for 1-3h, filtering, concentrating the filtrate under reduced pressure to about 20% of the initial volume, separating and purifying with cation exchange resin (such as 732 cation exchange resin or Dowex 50 cation exchange resin, etc.), eluting with water 6-10 times the column volume, collecting eluate A; then using ammonia water with the pH value of 8-11 as an eluting solvent, collecting to obtain an eluent B, adjusting the pH value of the eluent B to be neutral by using dilute hydrochloric acid, concentrating under reduced pressure to obtain a paste, adding 90-95% ethanol which is 3-8 times of the weight of the paste to dissolve, filtering, standing the filtrate at low temperature (0-4 ℃) overnight to separate out crystals, and drying the crystals to obtain theanine with the purity of over 80%;
separating and purifying the eluent A with macroporous adsorbent resin (such as D101 or AB-8 macroporous adsorbent resin), washing with water until sugar-free solution flows out (determining sugar-free when Molish reaction is negative), washing with 40-90% ethanol 4-8 times column volume, collecting eluate, concentrating under reduced pressure until relative density is 0.9-1.1, and spray drying (air inlet temperature 140 deg.C, air outlet temperature 100 deg.C) to obtain tea polyphenols with purity of above 70%.
Specifically, the tea pigment can be directly purchased from common commercial products, and can also be prepared by adopting the following steps: mixing green tea with petroleum ether or ethyl acetate 6-10 times of green tea, reflux extracting (2-3 times for 1-2 hr each time), and concentrating the extractive solution under reduced pressure to obtain tea pigment with purity of over 50%.
Specifically, the jasmine essential oil can be directly purchased from common commercial products, and can also be prepared by adopting the following steps: pulverizing flos Jasmini sambac, and performing CO treatment 2 Super clinical medicineExtracting at 20-60 deg.C under 10-20MPa for 1-6h to obtain flos Jasmini sambac essential oil.
Further, the safflower extract, the salvia extract, the pueraria extract, the dandelion extract, the feather cockscomb seed extract, the atractylodes extract, the cluster mallow seed extract and the liquorice extract can be directly purchased from common commercial products, and can also be prepared by adopting the following steps: respectively mixing the raw material medicines of safflower, salvia miltiorrhiza, kudzu root, dandelion, feather cockscomb seed, rhizoma atractylodis, cluster mallow seed or liquorice with water which is 10-20 times of the weight of the raw material medicines, decocting for 1-2h, filtering, concentrating the filtrate under reduced pressure until the relative density is 0.9-1.1, and performing spray drying (the air inlet temperature is 140-.
The invention also provides a preparation method of the hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy, which specifically comprises the following steps:
1) mixing tea polyphenols, theanine, Carthami flos extract, Saviae Miltiorrhizae radix extract, radix Puerariae extract, herba Taraxaci extract, semen Celosiae extract, rhizoma Atractylodis extract, semen Abutili extract, Glycyrrhrizae radix extract, part of polymer material, citric acid and purified water to form water phase;
2) mixing tea leaf essential oil, tea pigment, jasmine essential oil, glycerol, sorbitol, aluminum hydroxide and the balance of high polymer material uniformly to form a glycerol phase;
3) uniformly stirring the water phase and the glycerol phase to obtain a crude gel product; removing bubbles by using a vacuum defoaming stirrer, uniformly coating on non-woven fabric, laminating, and cooling to obtain the hydrogel eye patch.
In the hydrogel eye patch formula for the adjuvant therapy of central serous chorioretinopathy, the traditional Chinese medicine raw materials have the following effects:
the record of Shennong Ben Cao Jing records that the tea leaves taken for a long time can 'ease heart, tonify qi, lighten body and resist aging'. In the Ming Dynasty, the tea book of Yuan Qing is recorded: the tea has effects of quenching thirst, resolving food stagnation, eliminating phlegm, promoting urination, improving eyesight, benefiting intelligence, relieving restlessness, and removing greasiness. According to xi Rubia, the number of prescriptions for treating eye diseases is 130 in all the tea-containing prescriptions in all generations. Modern pharmacological research proves that the tea has multiple effects of resisting oxidation, resisting inflammation, resisting cancer, reducing blood pressure, reducing blood fat, protecting heart vessels and the like. The tea is rich in tea essential oil, tea polyphenol, tea pigment, tea polysaccharide, theanine and other components. The tea essential oil is essence in tea, has pleasant tea fragrance, and has effects of resisting oxidation and relieving nerve. Tea polyphenols have strong antioxidant effect, and can inhibit collagenase and elastase, prevent elastin content from decreasing or denaturing, maintain skin elasticity, and remove wrinkle. In addition, tea polyphenols can enhance resistance and elasticity of capillary vessel, increase blood flow, promote microcirculation of skin blood, and promote blood circulation for removing blood stasis. The research of Wangyuefei and the like finds that the tea polyphenol can enhance the oxidation resistance of the liver of a mouse and inhibit the liver injury caused by lipid peroxidation, thereby ensuring the normal function of the liver. Theanine is a non-protein amino acid in tea, is a main functional component of tea, and has physiological activities of resisting oxidation, resisting aging, relaxing nervous tension, protecting nervous system, etc. The tea pigment is a specific pure natural edible pigment in tea, mainly comprises theaflavin, theabrownin, thearubigins and theaviridin, can effectively reduce the formation of free radicals and inhibit lipid peroxidation, thereby having the function of resisting aging, and simultaneously having pharmacological actions of reducing blood fat, resisting atherosclerosis, enhancing immunologic function, improving microcirculation and the like.
The jasmine essential oil has the following effects: the jasmine essential oil has the effects of promoting blood circulation, removing blood stasis and soothing nerves, and is extremely relaxed. The jasmine essential oil is combined with the tea essential oil, so that the jasmine tea has jasmine green tea faint scent, can relieve nerves, relax body and mind and relax eyes, and has the effects of moisturizing, resisting wrinkles and the like.
Safflower, a dried flower of safflower belonging to the genus Carthamus of the family Compositae, is warm in nature, pungent in taste, and has the effects of activating blood and dredging meridians, removing blood stasis and relieving pain, and detoxifying, which were recorded in "Kaibao Bencao". Safflower contains rich active substances such as flavonoid, polysaccharide and yellow pigment, and has effects of inhibiting inflammation, resisting oxidation and cancer, inhibiting tyrosinase activity, and preventing cerebral or myocardial ischemia reperfusion injury. The safflower has the functions of changing the rheological property of blood, improving microcirculation, reducing blood viscosity and the like.
Dan Shen is slightly cold in nature and bitter in taste, entering heart and liver meridians. Has the effects of promoting blood circulation, regulating menstruation, removing blood stasis, relieving pain, cooling blood, resolving carbuncle, relieving restlessness and tranquilizing mind. Has effects in improving microcirculation, softening blood vessel, and improving myocardium. The salvia miltiorrhiza bunge and the main components thereof also have obvious protective effect on liver injury models prepared from carbon tetrachloride, D-galactosamine, alcohol and the like. Clinically, Dan and hong Hua are often combined to treat blood stasis and pain.
Radix Puerariae has effects of expelling pathogenic factors from muscles, reducing fever, promoting eruption, promoting fluid production, quenching thirst, invigorating yang and relieving diarrhea. The kudzuvine root has the efficacy of protecting the liver, is not easy to generate side effect, and can effectively assist in treating liver diseases. The pueraria flavonid has obvious protective effect on chronic liver injury animal models, and the puerarin which is the main active ingredient in the pueraria flavonid has the functions of resisting myocardial fibrosis injury, relaxing blood vessels, resisting artery calcification and atherosclerosis, promoting angiogenesis, improving micro blood flow, resisting platelet aggregation, reducing fat, resisting diabetes and the like. Puerarin can relieve oxidative stress injury caused by acute alcoholism, thereby protecting liver.
The dandelion and the dandelion are bitter in taste, cold in nature and non-toxic, enter liver and stomach channels, and have the effects of clearing away heat and toxic materials, reducing swelling and dissipating stagnation, and inducing diuresis for treating stranguria. Mainly contains chemical components of flavonoid, polysaccharide, organic acid substances and the like, and the effective components have the effects of improving the immunity of the organism, resisting bacteria, viruses, parasites, tumors, aging and the like.
Feather cockscomb seed, bitter and slightly cold. It enters liver meridian. Has the functions of clearing away liver heat, purging fire, improving eyesight and eliminating nebula. Can be used for treating liver heat with conjunctival congestion, nebula generation, blurred vision, and liver fire vertigo. Modern researches show that the Qinghuo has the effects of protecting liver, resisting cataract, resisting tumor, regulating immunity, resisting diabetes, resisting cardiovascular diseases, resisting bacteria and the like.
Cang Zhu is pungent and bitter in flavor and warm in nature. It enters spleen, stomach and liver meridians. Has the effects of eliminating dampness, strengthening spleen, dispelling pathogenic wind, dispelling cold, and improving eyesight. Mainly treats dampness obstruction of middle energizer, abdominal distention, diarrhea, edema, beriberi atrophy 36484, rheumatism and arthralgia, wind-cold type common cold, night blindness, dim eyes and unsmooth eyes. Pharmacological research shows that the rhizoma atractylodis and the extract thereof have the effects of resisting inflammation, resisting tumor, regulating immunity and the like.
Abelmoschus seeds, sweet in flavor and cold in nature. It enters large intestine, small intestine and bladder meridians. Is a common medicinal material of Mongolian, and has the effects of clearing away heat and toxic materials, promoting blood circulation, promoting urination, eliminating swelling and pain, and the like. Researches show that the malva seeds contain rich vegetable protein, anthocyanin and polysaccharide, and are beneficial to supplementing nutrition for patients, enhancing self resistance and repairing the capability of tissue damage.
Licorice root, radix Glycyrrhizae is sweet in flavor and neutral in nature. It enters heart, lung, spleen and stomach meridians. Has the effects of invigorating spleen and replenishing qi, clearing away heat and toxic materials, eliminating phlegm and stopping cough, relieving spasm and pain, and harmonizing the medicines.
In the formula of the hydrogel eye patch for assisting in treating central serous chorioretinopathy, tea essential oil, tea polyphenol, theanine, tea pigment, jasmine essential oil, a safflower extract, a salvia miltiorrhiza extract, a radix puerariae extract, a dandelion extract, a feather cockscomb seed extract, a rhizoma atractylodis extract, a cluster mallow seed extract and a liquorice extract are used as main functional components, a high polymer material is used as a hydrogel matrix, propylene glycol or glycerol is used as a humectant and a medicinal component dissolving agent, citric acid is used as a pH regulator, sorbitol is used as a humectant, and aluminum hydroxide is used as a cross-linking agent; compared with the prior art, the hydrogel eye patch has the following beneficial effects:
1) the hydrogel eye patch can effectively assist postoperative and traditional Chinese medicine and the like in treating central serous chorioretinopathy, can shorten the course of disease and improve vision, and has the effects of soothing nerves, resisting wrinkles and the like. The eye patch can be carried about and is convenient to use;
2) the effective components of the hydrogel eye mask traditional Chinese medicine are extracted from medicine-food homologous and conventional traditional Chinese medicines, and have no toxic or side effects and the like.
Detailed Description
The technical solution of the present invention is further described in detail with reference to the following examples, but the scope of the present invention is not limited thereto.
Example 1
A hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy is prepared from the following raw materials in percentage by weight: 0.01% of tea essential oil, 0.2% of tea polyphenol, 0.5% of theanine, 0.2% of tea pigment, 0.01% of jasmine essential oil, 0.5% of safflower extract, 0.5% of salvia miltiorrhiza extract, 0.8% of kudzuvine root extract, 0.8% of dandelion extract, 1.0% of feather cockscomb seed extract, 0.2% of rhizoma atractylodis extract, 0.5% of cluster mallow seed extract, 0.5% of liquorice extract, 8% of polyacrylamide, 11% of sodium polyacrylate, 23% of glycerol, 0.2% of citric acid, 1% of sorbitol, 0.1% of aluminum hydroxide and 50.98% of purified water.
The preparation method of the tea essential oil comprises the following steps: pulverizing green tea (40 mesh), and performing CO treatment 2 Performing supercritical extraction at 30 deg.C under 10MPa for 2 hr to obtain tea essential oil. The preparation method of the jasmine essential oil refers to tea essential oil.
The preparation method of the theanine and the tea polyphenol comprises the following steps:
CO generated in the preparation process of the tea essential oil 2 Adding water which is 10 times of the weight of the tea leaves into the tea leaves after supercritical extraction, extracting for 1.5h at 40 ℃, filtering, extracting twice, combining filtrates of the two times, concentrating under reduced pressure to about 20% of the initial volume, separating and purifying by using 732 cation exchange resin, washing by using water which is 6 times of the column volume as an elution solvent, and collecting to obtain an eluent A; then, ammonia water with pH =8 is used as an elution solvent for washing, eluent B is collected and obtained, the pH of the eluent B is adjusted to be neutral by dilute hydrochloric acid, the eluent B is concentrated into paste under reduced pressure, 95% ethanol with the weight 8 times that of the paste is added for dissolving, the filtering is carried out, the filtrate is placed at low temperature (0-4 ℃) overnight for precipitating crystals, and the crystals are dried to obtain theanine with the purity of 80%. Separating and purifying the eluent A by using D101 macroporous adsorption resin, washing with a large amount of water until a sugar-free solution flows out (the molish reaction is negative), then washing with 40% ethanol with 4 times of column volume, collecting the eluent, concentrating under reduced pressure until the relative density is 1.1, and performing spray drying (the air inlet temperature is 140 ℃, and the air outlet temperature is 100 ℃) to obtain the tea polyphenol with the purity of more than 70%.
The preparation method of the tea pigment comprises the following steps: mixing green tea leaf with petroleum ether 6 times of green tea leaf, reflux extracting for 2 times (1 hr each time), mixing extractive solutions, and concentrating under reduced pressure to obtain tea pigment with purity of over 50%.
The safflower extract, the salvia extract, the kudzuvine root extract, the dandelion extract, the feather cockscomb seed extract, the atractylodes rhizome extract, the cluster mallow seed extract and the liquorice extract are prepared by adopting the following steps: respectively mixing the raw material medicines of safflower, salvia miltiorrhiza, kudzu root, dandelion, feather cockscomb seed, rhizoma atractylodis, cluster mallow seed and liquorice with water 15 times the weight of the raw material medicines, decocting for 1h (twice decocting), filtering, combining the two filtrates, concentrating under reduced pressure until the relative density is 1.0, and performing spray drying (the air inlet temperature is 140-.
The preparation method of the hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy comprises the following specific steps:
1) mixing tea polyphenols, theanine, Carthami flos extract, Saviae Miltiorrhizae radix extract, radix Puerariae extract, herba Taraxaci extract, semen Celosiae extract, rhizoma Atractylodis extract, semen Abutili extract, Glycyrrhrizae radix extract, part of polymer material (polyacrylamide and sodium polyacrylate), citric acid and purified water, stirring to obtain water phase;
2) fully stirring and uniformly mixing tea essential oil, tea pigment, jasmine essential oil, glycerol, sorbitol, aluminum hydroxide and the balance of high polymer materials to form a glycerol phase, wherein no blocky solid exists in the glycerol phase;
3) adding the water phase into the glycerol phase, and continuously stirring for 30 minutes to uniformly mix to obtain a gel crude product; removing bubbles by using a vacuum defoaming stirrer to form a bubble-free hydrogel product, then uniformly coating the bubble-free hydrogel product on non-woven fabric by using a hydrogel coating machine, coating the non-woven fabric to the thickness of 1mm, covering a film, and cooling to obtain the hydrogel eye patch.
Example 2
A hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy is prepared from the following raw materials in percentage by weight: 0.02% of tea essential oil, 0.3% of tea polyphenol, 0.4% of theanine, 0.1% of tea pigment, 0.04% of jasmine essential oil, 0.5% of safflower extract, 0.5% of salvia miltiorrhiza extract, 0.4% of kudzu root extract, 0.4% of dandelion extract, 0.8% of feather cockscomb seed extract, 1.0% of rhizoma atractylodis extract, 0.6% of cluster mallow seed extract, 0.2% of liquorice extract, 10% of polyacrylic acid, 10% of sodium polyacrylate, 30% of glycerol, 0.4% of citric acid, 1.8% of sorbitol, 0.2% of aluminum hydroxide and 42.34% of purified water.
The preparation method of the tea essential oil comprises the following steps: pulverizing green tea (40 mesh), and performing CO treatment 2 Performing supercritical extraction at 30 deg.C under 12MPa for 5 hr to obtain tea essential oil. The preparation method of the jasmine essential oil refers to tea essential oil.
The preparation method of the theanine and the tea polyphenol comprises the following steps:
CO generated in the preparation process of the tea essential oil 2 Adding water which is 20 times of the weight of the tea leaves into the tea leaves after supercritical extraction, extracting for 2h at 60 ℃, filtering, extracting twice, combining filtrates of the two times, concentrating under reduced pressure to about 20% of the initial volume, separating and purifying by Dowex 50 cation exchange resin, washing by using water which is 6 times of the column volume as an eluting solvent, and collecting to obtain an eluent A; then, ammonia water with the pH =9 is used as an elution solvent for washing, an eluent B is collected and obtained, the pH of the eluent B is adjusted to be neutral by dilute hydrochloric acid, the eluent B is concentrated into a paste under reduced pressure, 90% ethanol which is 5 times of the weight of the paste is added for dissolving, the filtering is carried out, the filtrate is placed at low temperature (0-4 ℃) overnight to separate out theanine crystals, and the theanine crystals with the purity of 80% are obtained after drying the crystals. Separating and purifying the eluent A by AB-8 macroporous adsorption resin, washing with a large amount of water until a sugar-free solution flows out (molish reaction is negative), then washing with 70% ethanol 6 times the column volume, collecting the eluent, concentrating under reduced pressure until the relative density is 1.0, and performing spray drying (air inlet temperature is 140 ℃, air outlet temperature is 100 ℃) to obtain the tea polyphenol with the purity of more than 70%.
The preparation method of the tea pigment comprises the following steps: mixing green tea with ethyl acetate 10 times of green tea, reflux extracting for 2 times (2 hr each time), mixing extractive solutions, and concentrating under reduced pressure to obtain tea pigment with purity of over 50%.
The safflower extract, the salvia extract, the kudzu root extract, the dandelion extract, the feather cockscomb seed extract, the rhizoma atractylodis extract, the cluster mallow seed extract and the liquorice extract are prepared by the following steps: mixing the raw material medicines of safflower, salvia miltiorrhiza, kudzu root, dandelion, feather cockscomb seed, rhizoma atractylodis, cluster mallow seed and liquorice with 14 times of water by weight of the raw material medicines respectively, decocting for 1h (twice decoction), filtering, combining the filtrates obtained twice, concentrating under reduced pressure until the relative density is 1.05, and performing spray drying (the air inlet temperature is 140-.
The preparation method of the hydrogel eye patch for assisting in treating central serous chorioretinopathy comprises the following specific steps:
1) mixing tea polyphenols, theanine, Carthami flos extract, Saviae Miltiorrhizae radix extract, radix Puerariae extract, herba Taraxaci extract, semen Celosiae extract, rhizoma Atractylodis extract, semen Abutili extract, Glycyrrhrizae radix extract, part of polymer material (polyacrylic acid and sodium polyacrylate), citric acid and purified water, and stirring to obtain water phase;
2) fully stirring and uniformly mixing tea essential oil, tea pigment, jasmine essential oil, glycerol, sorbitol, aluminum hydroxide and the balance of high polymer materials to form a glycerol phase, wherein no blocky solid exists in the glycerol phase;
3) adding the water phase into the glycerol phase, and continuously stirring for 30 minutes to uniformly mix to obtain a crude gel product; removing bubbles by using a vacuum defoaming stirrer to form a bubble-free hydrogel product, uniformly coating the hydrogel product on non-woven fabrics by using a hydrogel coating machine, coating the non-woven fabrics to the thickness of 1mm, laminating, and cooling to obtain the hydrogel eye patch.
Example 3
A hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy is prepared from the following raw materials in percentage by weight: 0.04% of tea essential oil, 0.6% of tea polyphenol, 0.2% of theanine, 0.2% of tea pigment, 0.04% of jasmine essential oil, 0.5% of safflower extract, 0.5% of salvia miltiorrhiza extract, 1.0% of kudzuvine root extract, 1.0% of dandelion extract, 1.5% of feather cockscomb seed extract, 1.2% of rhizoma atractylodis extract, 0.8% of cluster mallow seed extract, 0.2% of liquorice extract, 12% of polymethacrylic acid, 10% of sodium polyacrylate, 3% of sodium carboxymethylcellulose, 25% of glycerol, 0.3% of citric acid, 2% of sorbitol, 0.3% of aluminum hydroxide and 36.62% of purified water.
The preparation method of the tea essential oil comprises the following steps: pulverizing green tea (40 mesh), and subjecting to CO extraction 2 Is obtained by supercritical extractionObtaining the tea essential oil, wherein the extraction temperature is 60 ℃, the pressure is 20MPa, and the extraction time is 1.5 h.
The preparation method of the jasmine essential oil refers to tea essential oil.
The preparation method of the theanine and the tea polyphenol comprises the following steps:
CO generated in the preparation process of the tea essential oil 2 Adding water 30 times the weight of the tea leaves into the tea leaves subjected to supercritical extraction, extracting for 3h at 90 ℃, filtering, extracting twice, combining filtrates, concentrating under reduced pressure to about 20% of the initial volume, separating and purifying by Dowex 50 cation exchange resin, washing by using water 10 times the column volume as an eluting solvent, and collecting to obtain an eluent A; then, ammonia water with pH =10 is used as an elution solvent for washing, eluent B is collected and obtained, the pH of the eluent B is adjusted to be neutral by dilute hydrochloric acid, the eluent B is concentrated into paste under reduced pressure, ethanol which is 4 times of the weight of the paste and is 92 percent is added for dissolving, the filtering is carried out, the filtrate is placed at low temperature (0-4 ℃) overnight to precipitate theanine crystals, and the crystals are dried to obtain theanine with the purity of 80 percent. Separating and purifying the eluent A by AB-8 macroporous adsorption resin, washing with a large amount of water until sugar-free solution flows out (molish reaction is negative), then washing with 90% ethanol with 8 times of column volume, collecting the eluent, concentrating under reduced pressure until the relative density is 0.9, and spray drying (air inlet temperature is 140 ℃, air outlet temperature is 100 ℃) to obtain the tea polyphenol with the purity of more than 70%.
The preparation method of the tea pigment comprises the following steps: mixing green tea with ethyl acetate 10 times of green tea, reflux extracting for 3 times (each time for 1 hr), mixing extractive solutions, and concentrating under reduced pressure to obtain tea pigment with purity of over 50%.
The safflower extract, the salvia extract, the kudzu root extract, the dandelion extract, the feather cockscomb seed extract, the rhizoma atractylodis extract, the cluster mallow seed extract and the liquorice extract are prepared by the following steps: mixing the raw material medicines of safflower, salvia miltiorrhiza, kudzu root, dandelion, feather cockscomb seed, rhizoma atractylodis, cluster mallow seed or liquorice with water of 20 weight times of the raw material medicines respectively, decocting for 2 hours (the filter residue is decocted once again, and the decoction is carried out twice in total), filtering, combining the two filtrates, and concentrating under reduced pressure until the relative density is 1.1, and carrying out spray drying (the air inlet temperature is 140 ℃ and the air outlet temperature is 100 ℃ and 140 ℃).
The preparation method of the hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy comprises the following specific steps:
1) mixing tea polyphenols, theanine, Carthami flos extract, Saviae Miltiorrhizae radix extract, radix Puerariae extract, herba Taraxaci extract, semen Celosiae extract, rhizoma Atractylodis extract, semen Abutili extract, Glycyrrhrizae radix extract, part of high molecular material (polymethacrylic acid, sodium polyacrylate, and sodium carboxymethylcellulose), citric acid and purified water, stirring to obtain water phase;
2) fully stirring and uniformly mixing tea essential oil, tea pigment, jasmine essential oil, glycerol, sorbitol, aluminum hydroxide and the balance of high polymer materials to form a glycerol phase, wherein no blocky solid exists in the glycerol phase;
3) adding the water phase into the glycerol phase, and continuously stirring for 30 minutes to uniformly mix to obtain a crude gel product; removing bubbles by using a vacuum defoaming stirrer to form a bubble-free hydrogel product, uniformly coating the hydrogel product on non-woven fabrics by using a hydrogel coating machine, coating the non-woven fabrics to the thickness of 1mm, laminating, and cooling to obtain the hydrogel eye patch.
Statistical data of clinical trials
Clinical cases: the total 80 people are divided into observation group and control group according to random principle, and the age is 25-55 years. 40 cases (40 eyes) in the observation group, 32 cases in men, 8 cases in women, and 3 days-1.5 years in the course of disease, 40 cases (40 eyes) in the control group, 34 cases in men, 6 cases in women, and 3 days-2 years in the course of disease. The comparison difference between two groups of general data is not statistically significant (P > 0.05) and is comparable. Patients with internal eye surgery history and eye trauma history are excluded, and patients with serious cardiovascular and cerebrovascular diseases, keratitis, glaucoma, uveitis and other diseases are excluded.
The diagnosis standard of case:
symptoms are: the vision is blurred suddenly, the center of the visual field is blocked by a light shadow, the vision can be deformed and diminished, and the disease course is different. Eyes have no red swelling and hot pain, and no history of trauma.
Special examination: the degree of visual impairment varies from 0.1 to 0.8, and often there are deformities or dark spots when examined using an Amsler grid form. The anterior segment of the eye is checked to be free of abnormality, the retina of the posterior pole part can be seen in the eye fundus examination, the macula lutea is mostly taken as the center, the reflection is enhanced, the macula lutea is in a halo shape, and the fovea centralis is scattered in reflection. The severe patients showed discoid bulging of the macula retina, with no bleeding. No abnormality was found.
The unique expression of fundus angiography is as follows: the visible pigment epithelium layer plane in the vein phase of radiography has one or more strong fluorescence leakage focuses, the fluorescence leakage gradually occurs along with the prolonging of the radiography time, the fluorescence leakage is enlarged like ink or mushroom, the fluorescence is accumulated under the nerve epithelium at the later stage, a disc-shaped nerve epithelium separation area is delineated, and the optic disc and retinal blood vessels do not have obvious abnormal fluorescence.
The treatment method comprises the following steps:
the control group is administered with oral conventional medicine, and the compound XUESHUANTONG Capsule is administered at a dose of 1.5 g/time and 3 times/day for 2 months.
The treatment group used the eye patch of the present invention on the basis of the treatment of the control group, 2 times a day, once applied for 15-20 minutes, and continuously applied for 2 months.
The curative effect standard is as follows:
and (3) curing: the vision is recovered to the level or above before the disease, the retinal edema is resolved, the macula is exudated and absorbed, and the fluorescence contrast seepage disappears;
the method has the following advantages: vision is improved by 3 lines or more, retinal edema is reduced, macular exudation is reduced, and fluorography exudation is weakened.
And (4) invalidation: vision is unchanged or decreased, retinal edema is increased or not reduced, macular exudation is increased or not absorbed, and fluorography is leaky or not improved.
The treatment results are shown in table 1. After two months of treatment, the total effective rate of the control group is 80.0 percent, the total effective rate of the treatment group is 97.5 percent, and the effective rate of the treatment is greatly improved, which shows that the eye patch has the function of assisting in treating central serous chorioretinopathy.
TABLE 1 comparison of the two groups of therapeutic effects after 2 months of treatment
| Group of | Cure of disease | Is effective | Invalidation | Total effective rate |
| Treatment group | 7 | 32 | 1 | 97.5% |
| Control group | 5 | 27 | 8 | 80.0% |
Claims (5)
1. The hydrogel eye mask for assisting in treating the central serous chorioretinopathy is characterized by comprising the following raw materials in percentage by weight: 0.01-0.04% of tea essential oil, 0.2-0.8% of tea polyphenol, 0.1-0.6% of theanine, 0.1-0.6% of tea pigment, 0.01-0.04% of jasmine essential oil, 0.2-1.0% of safflower extract, 0.2-1.0% of salvia extract, 0.2-1.5% of kudzu root extract, 0.2-1.5% of dandelion extract, 0.2-1.5% of feather cockscomb seed extract, 0.2-1.5% of rhizoma atractylodis extract, 0.2-1.0% of cluster mallow seed extract, 0.2-1.0% of liquorice extract, 10-25% of high polymer material, 20-30% of glycerol, 0.1-0.5% of citric acid, 1-3% of sorbitol, 0.1-0.3% of aluminum hydroxide and the balance of purified water;
the jasmine essential oil is prepared by the following steps: mixing flos Jasmini sambacCrushing pollen, and treating with CO 2 Performing supercritical extraction to obtain flos Jasmini sambac essential oil, wherein the extraction temperature is 20-60 deg.C, the pressure is 10-20MPa, and the extraction time is 1-6 h;
the safflower extract, the salvia extract, the kudzuvine root extract, the dandelion extract, the feather cockscomb seed extract, the atractylodes rhizome extract, the cluster mallow seed extract and the liquorice extract are prepared by the following steps: mixing Carthami flos, Saviae Miltiorrhizae radix, radix Puerariae, herba Taraxaci, semen Celosiae, rhizoma Atractylodis, semen Abutili or Glycyrrhrizae radix with 10-20 weight times of water, decocting for 1-2 hr, filtering, concentrating the filtrate under reduced pressure to relative density of 0.9-1.1, and spray drying.
2. The hydrogel eye patch for adjunctive treatment of central serous chorioretinopathy according to claim 1, wherein the polymeric material is one or a mixture of two or more of sodium polyacrylate, polyacrylic acid, polymethacrylic acid, polyvinyl alcohol, polyacrylamide and sodium carboxymethylcellulose.
3. The hydrogel eye patch for the adjuvant treatment of central serous chorioretinopathy according to claim 1, wherein the tea essential oil, the tea polyphenol and the theanine are prepared by the following steps:
pulverizing green tea, and performing CO treatment 2 Performing supercritical extraction at 20-60 deg.C under 10-20MPa for 1-6 hr to obtain tea essential oil;
CO is introduced into 2 Adding water into the tea leaves subjected to supercritical extraction, extracting at 40-90 deg.C for 1-3h, filtering, concentrating the filtrate under reduced pressure, separating and purifying with cation exchange resin, eluting with water, and collecting eluate A; then using ammonia water with the pH value of 8-11 as an eluting solvent, collecting to obtain an eluent B, adjusting the pH value of the eluent B to be neutral by using dilute hydrochloric acid, concentrating under reduced pressure to form a paste, adding 90-95% ethanol with the weight of 3-8 times of that of the paste to dissolve, filtering, standing the filtrate at the low temperature of 0-4 ℃ overnight to precipitate crystals, and drying the crystals to obtain theanine;
separating and purifying the eluate A with macroporous adsorbent resin, washing with water until sugar-free solution flows out, washing with 40-90% ethanol, collecting eluate, concentrating under reduced pressure until relative density is 0.9-1.1, and spray drying to obtain tea polyphenols.
4. The hydrogel eye patch for the adjuvant treatment of central serous chorioretinopathy according to claim 1, wherein the tea pigment is prepared by the following steps: mixing green tea with petroleum ether or ethyl acetate 6-10 times of green tea, reflux extracting, and concentrating the extractive solution under reduced pressure to obtain tea pigment.
5. The preparation method of the hydrogel eye patch for the adjuvant therapy of central serous chorioretinopathy according to any one of claims 1 to 4, which is characterized by comprising the following steps:
1) mixing tea polyphenols, theanine, Carthami flos extract, Saviae Miltiorrhizae radix extract, radix Puerariae extract, herba Taraxaci extract, semen Celosiae extract, rhizoma Atractylodis extract, semen Abutili extract, Glycyrrhrizae radix extract, part of polymer material, citric acid and purified water to form water phase;
2) mixing tea leaf essential oil, tea pigment, jasmine essential oil, glycerol, sorbitol, aluminum hydroxide and the balance of high polymer material uniformly to form a glycerol phase;
3) uniformly stirring the water phase and the glycerol phase to obtain a crude gel product; removing bubbles by using a vacuum defoaming stirrer, uniformly coating on non-woven fabric, laminating, and cooling to obtain the hydrogel eye patch.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110008288.7A CN112426462B (en) | 2021-01-05 | 2021-01-05 | Hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110008288.7A CN112426462B (en) | 2021-01-05 | 2021-01-05 | Hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112426462A CN112426462A (en) | 2021-03-02 |
| CN112426462B true CN112426462B (en) | 2022-08-30 |
Family
ID=74697161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110008288.7A Active CN112426462B (en) | 2021-01-05 | 2021-01-05 | Hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112426462B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210841A (en) * | 2011-05-18 | 2011-10-12 | 刘永华 | Chinese medicinal preparation for treating central serous retinopathy |
| CN102827896A (en) * | 2012-09-14 | 2012-12-19 | 向华 | Method for extracting theaflavin and theanine from tea leaves |
| CN104491403A (en) * | 2014-12-08 | 2015-04-08 | 四川金堂海纳生物医药技术研究所 | Medicine for treating central retinochoroiditis and preparation method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101798355B (en) * | 2010-04-08 | 2015-02-11 | 晋江市恒源科技开发有限公司 | Method for integrated separation and extraction of tea polysaccharide, theanine, polyphenol and caffeine |
| CN112022938B (en) * | 2020-10-22 | 2022-03-15 | 河南省纳普生物技术有限公司 | Hydrogel eye patch for relieving asthenopia and preventing myopia and preparation method thereof |
-
2021
- 2021-01-05 CN CN202110008288.7A patent/CN112426462B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210841A (en) * | 2011-05-18 | 2011-10-12 | 刘永华 | Chinese medicinal preparation for treating central serous retinopathy |
| CN102827896A (en) * | 2012-09-14 | 2012-12-19 | 向华 | Method for extracting theaflavin and theanine from tea leaves |
| CN104491403A (en) * | 2014-12-08 | 2015-04-08 | 四川金堂海纳生物医药技术研究所 | Medicine for treating central retinochoroiditis and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112426462A (en) | 2021-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102319372B (en) | Preparation method of Chinese medicinal lotion for treating heart channel stagnated heat bedsores | |
| CN102366564B (en) | Preparation method of traditional Chinese medicine lotion for treating red urine-type bedsore | |
| CN102327517B (en) | Preparation method of traditional Chinese medicine lotion for treating wind-fire type decubitus ulcers | |
| CN112245493A (en) | Eye-protecting health-care patch and preparation method thereof | |
| CN112007017A (en) | Eye-protecting health-care patch and preparation method thereof | |
| CN112426462B (en) | Hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy and preparation method thereof | |
| CN102631571B (en) | Method for preparing traditional Chinese medicine lotion for treating drinking-type furuncle on sole | |
| CN102755549B (en) | Drug for curing cataract and preparation method thereof | |
| CN111759894A (en) | A Chinese medicinal composition for treating myopia, and its preparation method | |
| CN104398797A (en) | Traditional Chinese medicine composition for treating children hydrocephalus and preparation method thereof | |
| CN104523981A (en) | Traditional Chinese medicine preparation for treating optic neuritis and preparation method | |
| CN115089633B (en) | Composition for preventing and treating myopia, eye mask and preparation method | |
| CN104306546A (en) | A traditional Chinese medicine composition used for treating optic atrophy, and decoctions, pills and powder of the composition | |
| CN102631575B (en) | Method for preparing traditional Chinese medicine (TCM) lotion for treating heat toxicity type pustule on sole | |
| CN114452365B (en) | Traditional Chinese medicine preparation for treating chalazion | |
| CN102940753A (en) | Pills for treating glaucoma and preparation method | |
| CN110151922B (en) | Traditional Chinese medicine composition for treating angina pectoris complicated with hypertension and preparation method thereof | |
| CN105596566A (en) | Traditional Chinese medicine for treating fundus hemorrhage and preparation method thereof | |
| CN101804137B (en) | Chinese medicine film preparation used in plasma filtering device | |
| CN105641255A (en) | Eye drops capable of diminishing inflammation, inducing resuscitation and improving eyesight and preparation method of eye drops | |
| CN106491730A (en) | A kind of treat Chinese medicine composition of glaucoma and preparation method thereof | |
| CN106309779A (en) | Eyedrop for relieving eye fatigue and preparation method thereof | |
| CN104771638A (en) | Traditional Chinese medicine composition for treating optic atrophy | |
| CN104740200A (en) | Traditional Chinese medicine spray for treating nasal obstruction caused by chronic nasosinusitis and preparation method of traditional Chinese medicine spray | |
| CN104606529A (en) | A traditional Chinese medicine decoction for treating trachoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |